Member News, Robotics
member news, ReWalk Robotics, robotics

ReWalk Robotics ReStore Soft Exoskeleton Expands Clinical Trials

The following post originally appeared on The Robot Report.


Clinical trials for the ReWalk Robotics ReStore soft exoskeleton are expanding to five research centers in the United States. The centers involved in the ReWalk Robotics ReStore trials include the Shirley Ryan AbilityLab (Chicago), Spaulding Rehabilitation Hospital (Boston), the MossRehab Stroke and Neurological Disease Center (Elkins Park, PA), TIRR Memorial Hermann (Houston), and the Kessler Foundation (East Hanover, NJ).

The ReWalk Robotics ReStore soft exoskeleton is expected to launch in the first half of 2019 in Europe and the US. Designed to assist stroke patients, the ReWalk Robotics ReStore is used as a gait therapy solution, providing coordinated plantarflexion and dorsiflexion assistance to a patient’s foot and ankle. ReWalk plans to price the system at under $20,000.

Enrollment for the company’s multi-center study is ongoing.

“We expect that the expansion of our clinical study to these renowned research organizations will bring the ReStore exo-suit closer to CE and FDA clearance,” says ReWalk CEO Larry Jasinski. “The ReStore will offer an immediate and cost-effective solution for the more than three million stroke patients in the U.S. with lower limb disabilities. We are thrilled to be partnering with the most prestigious institutions in the world to bring our product to market.”

“The ReWalk Robotics ReStore is an unobtrusive wearable robotic technology that can seamlessly interact with and enhance everyday clinical care, allowing stroke patients to walk effectively and efficiently,” lead investigator Arun Jayaraman added.

Continue reading (and watch a video of the Soft Exo Suit in action) at The Robot Report.

Upcoming Events


Related Articles